Daniel Blessing
Daniel is a biotechnology scientist with 10 years' experience in pharmaceutical biotechnology, particularly in the various translational aspects of drug development and production.
As a post-doctoral fellow at the CHUV, Daniel worked on methods for the delivery and modulation of therapeutic genes using various modalities, including antisense oligonucleotides.
During his PhD at the University of Lausanne and the Ecole Polytechnique Fédérale de Lausanne (EPFL), his work focused on developing new strategies for GMP-compliant manufacturing processes to support various gene therapy applications and clinical trials.
🗞️ HAYA Therapeutics has secured a deal worth up to USD 1 billion with Eli Lilly and company to develop treatments for obesity using its RNA platform. Discover more here